Old Web
English
Sign In
Acemap
>
authorDetail
>
J. M. van Rooijen
J. M. van Rooijen
University Medical Center Groningen
Medicine
Renal function
Pharmacology
Progressive disease
Renal cell carcinoma
3
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group
2017
European Journal of Cancer
Johannes J.M. Kwakman
Lieke H.J. Simkens
J. M. van Rooijen
Aj van de Wouw
Olaf Loosveld
G-J M Creemers
Mathijs P. Hendriks
Maartje Los
R. J. Van Alphen
Marco B. Polee
Erik W. Muller
A.M.T. van der Velden
T. van Voorthuizen
M. Koopman
Linda Mol
E. van Werkhoven
C.J.A. Punt
Show All
Source
Cite
Save
Citations (1)
Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study
2014
European Journal of Cancer
J. M. van Rooijen
de Linda Munck
J.C. de Graaf
Sabine Siesling
de Elisabeth G. E. Vries
James E. Boers
Show All
Source
Cite
Save
Citations (8)
Hemodialysis no reason to withhold everolimus
2013
Cancer Chemotherapy and Pharmacology
J. M. van Rooijen
de Elisabeth G. E. Vries
Show All
Source
Cite
Save
Citations (4)
1